Abstract

Sarcoidosis and tuberculosis (TB) are two granulomatous diseases that often share overlapping clinical features, including uveitis. We measured 368 inflammation-related proteins in serum in both diseases, with and without uveitis from two distinct geographically separated cohorts: sarcoidosis from the Netherlands and TB from Indonesia. A total of 192 and 102 differentially expressed proteins were found in sarcoidosis and active pulmonary TB compared to their geographical healthy controls, respectively. While substantial overlap exists in the immune-related pathways involved in both diseases, activation of B cell activating factor (BAFF) signaling and proliferation-inducing ligand (APRIL) mediated signaling pathways was specifically associated with sarcoidosis. We identified a B-lymphocyte activation signature consisting of BAFF, TNFRSF13B/TACI, TRAF2, IKBKG, MAPK9, NFATC1, and DAPP1 that was associated with sarcoidosis, regardless of the presence of uveitis. In summary, a difference in B-lymphocyte activation is a key discriminative immunological feature between sarcoidosis/ocular sarcoidosis (OS) and TB/ocular TB (OTB).

Sarcoidosis patients exhibit higher level of serum B cell activation signature compared to tuberculosis, regardless of uveitis manifestation.

Details

Title
A serum B-lymphocyte activation signature is a key distinguishing feature of the immune response in sarcoidosis compared to tuberculosis
Author
Putera, Ikhwanuliman 1   VIAFID ORCID Logo  ; Schrijver, Benjamin 2 ; Kolijn, P. Martijn 2 ; van Stigt, Astrid C. 3   VIAFID ORCID Logo  ; ten Berge, Josianne C. E. M. 4 ; IJspeert, Hanna 5 ; Nagtzaam, Nicole M. A. 2 ; Swagemakers, Sigrid M. A. 6   VIAFID ORCID Logo  ; van Laar, Jan A. M. 7 ; Agrawal, Rupesh 8 ; Rombach, Saskia M. 7 ; van Hagen, P. Martin 9 ; La Distia Nora, Rina 10 ; Dik, Willem A. 2   VIAFID ORCID Logo 

1  Erasmus University Medical Center, Department of Ophthalmology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Erasmus University Medical Center, Department of Internal Medicine Section Allergy & Clinical Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Erasmus University Medical Center, Laboratory Medical Immunology, Department of Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Cipto Mangunkusumo Hospital, Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia (GRID:grid.9581.5) (ISNI:0000 0001 2019 1471) 
2  Erasmus University Medical Center, Laboratory Medical Immunology, Department of Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X) 
3  Erasmus University Medical Center, Department of Internal Medicine Section Allergy & Clinical Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Erasmus University Medical Center, Laboratory Medical Immunology, Department of Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Erasmus University Medical Center, Academic Center for Rare Immunological Diseases (Rare Immunological Disease Center), Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X) 
4  Erasmus University Medical Center, Department of Ophthalmology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X) 
5  Erasmus University Medical Center, Laboratory Medical Immunology, Department of Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Erasmus University Medical Center, Academic Center for Rare Immunological Diseases (Rare Immunological Disease Center), Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X) 
6  Erasmus MC University Medical Center Rotterdam, Department of Bioinformatics, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X) 
7  Erasmus University Medical Center, Department of Internal Medicine Section Allergy & Clinical Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X) 
8  Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore, Singapore (GRID:grid.240988.f) (ISNI:0000 0001 0298 8161); Nanyang Technological University, Lee Kong Chian School of Medicine, Singapore, Singapore (GRID:grid.59025.3b) (ISNI:0000 0001 2224 0361); Duke NUS University, Ophthalmology and Visual Sciences Academic Clinical Program, Singapore, Singapore (GRID:grid.428397.3) (ISNI:0000 0004 0385 0924); Singapore Eye Research Institute, Singapore, Singapore (GRID:grid.272555.2) (ISNI:0000 0001 0706 4670); Moorfields Eye Hospital, London, United Kingdom (GRID:grid.439257.e) (ISNI:0000 0000 8726 5837) 
9  Erasmus University Medical Center, Department of Internal Medicine Section Allergy & Clinical Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X); Erasmus University Medical Center, Laboratory Medical Immunology, Department of Immunology, Rotterdam, the Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X) 
10  Cipto Mangunkusumo Hospital, Department of Ophthalmology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia (GRID:grid.9581.5) (ISNI:0000 0001 2019 1471) 
Pages
1114
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s42003-024-06822-1
ProQuest document ID
3102578198
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.